Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a…
Read More
A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on…
A new study reports that a protein formerly identified as a potential therapeutic target in pleural mesothelioma, CXCR4, might not be a relevant approach for the…
Even though 40 years have passed since their exposure to asbestos, workers’ risk of developing mesothelioma continues to rise, new research shows. Individuals exposed to asbestos four decades ago…
The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of…
Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell…
The calcium-binding protein calretinin is useful as a blood-based biomarker with high sensitivity to detect malignant mesothelioma, finds a study, “Calretinin as a blood-based biomarker for mesothelioma,” that…
Adding nintedanib to chemotherapy led to a 64 percent increase in the time it took for mesothelioma patients’ disease to progress, compared with chemo alone,…
French researchers have used mathematical modeling to select the best treatment schedule and dosing of Navelbine (vinorelbine) chemotherapy for mesothelioma and non-small cell lung cancer (NSCLC)…
Immunotherapy may be the way to tackle malignant pleural mesothelioma (MPM) after relapse, a new Phase 2 trial suggests. Using Opdivo (nivolumab) alone or in combination with…
